Sabinsa has developed Curcumin C3 Reduct, the only reductive metabolites of curcuminoids on the market to have been approved as a Novel Food by the European Food Safety Authority (EFSA). Easy to integrate into existing production processes and with the concentrated benefits of curcumin, C3 Reduct has been shown to boost organ health and deliver a range of other targeted functionalities.
Curcumin, the principal curcuminoid sourced from the spice turmeric, has gained increasing global recognition for its multiple health benefits, in particular its antioxidant and anti-inflammatory properties. As a result, the ingredient is used as a means of supporting healthy living and longevity, and in managing inflammation and joint soreness.
A principal advantage of C3 Reduct is that these benefits are concentrated and enhanced. C3 Reduct, wherein curcuminoids are already converted to Tetrahydrocurcuminoids (THC’s), means that the product is directly assimilated in the body as beneficial metabolites. This is important, as the metabolites are more bioavailable than the parent curcuminoids.
In fact, C3 Reduct is the only EFSA-approved product of its kind on the market. Other curcumin-based products have to deliver curcumin in large doses to offer functionality. With C3 Reduct however, manufacturers can avoid the need to up dosages or mix curcumin with other artificial additives to increase bioavailability. This is because C3 Reduct delivers active metabolites directly to the body.
Curcumin is also yellow in colour, which can lead to staining issues along the production line. C3 Reduct can also help product developers to overcome this issue, because THCs are colourless. Manufacturers therefore do not have to worry about staining or off-colours.
The purpose of this White Paper is to help product developers better understand the functional benefits of C3 Reduct, to identify formulation opportunities and to bring to market health and wellness products that meet consumer demands.